Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Santen Pharmaceutical
Biotech
RemeGen sells Asia rights to VEGF/FGF eye drug in $180M deal
China’s RemeGen has sold certain Asia rights to its phase 3-stage eye disease drug to Japan’s Santen for $34.8 million upfront.
James Waldron
Aug 19, 2025 7:18am
Verily plans digital eye care joint venture with Santen Pharma
Feb 4, 2020 12:59pm
Mixed late-stage data for Santen eye drug, but still plots FDA submission
Nov 28, 2016 9:12am
Santen snaps up glaucoma microshunt maker InnFocus for $225M
Jul 19, 2016 9:38am
